Loading stock data…
HRMY
$31.83+0.57 (+1.82%)
Market ClosedLast close May 1
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Harmony Biosciences Holdings, Inc. in the Healthcare sector is trading at $31.83. The stock is currently 22% below its 52-week high of $40.87, remaining 3.5% below its 200-day moving average. Technical signals show neutral RSI of 70 and bullish MACD crossover, explaining why HRMY maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 70) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$31.83
Potential Upside
87.2%
Whystock Fair Value$59.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$43.00+35.1%
Range$25.00 – $72.00
Fundamentals
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.86B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
11.84
Beta
Defensive asset. Lower volatility than the S&P 500.
0.89
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
20.79%
Volume
Today's trading volume
378,601
Recent News
Assessing Harmony Biosciences (HRMY) Valuation After Recent Share Price Momentum And Pipeline Expectations
What Harmony Biosciences Holdings (HRMY) Offers Investors Right Now Harmony Biosciences Holdings (HRMY) focuses on therapies for rare neurological diseases, giving investors exposure to a single revenue stream of US$868.453 million and net income of US$158.687 million. The company’s entire reported revenue comes from the United States, which keeps its geographic profile straightforward but concentrated in one market. See our latest analysis for Harmony Biosciences Holdings. At a share price...
Why Harmony Biosciences (HRMY) Reaffirmed 2026 Revenue Guidance and Hired a Markets-Focused CFO
Earlier in April 2026, Harmony Biosciences Holdings reiterated its 2026 net product revenue guidance of US$1.00–US$1.04 billion and appointed industry veteran Glenn Reicin as Chief Financial Officer and member of the Executive Team. By pairing reaffirmed guidance with a CFO known for capital markets expertise and scaling biopharma platforms, Harmony signaled a focus on financial discipline alongside growth initiatives. We’ll now examine how Harmony’s reiterated revenue outlook and Glenn...
Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?
Legend Biotech (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Harmony Biosciences Eyes $1B WAKIX Runway, Teases 2026 Pipeline Catalysts at Needham Conference
Harmony Biosciences (NASDAQ:HRMY) executives outlined 2026 priorities at Needham & Company’s Virtual Healthcare Conference, emphasizing continued growth for WAKIX and multiple late-stage pipeline readouts across sleep-wake and rare epilepsy indications. WAKIX outlook and commercial execution Pr
Harmony Biosciences Holdings (HRMY) Valuation After New COO And Board Appointments
Harmony Biosciences Holdings (HRMY) shares are in focus after the company named Peter Anastasiou as Chief Operating Officer and refreshed its board with experienced biotech leaders Troy Ignelzi and Geno J. Germano. See our latest analysis for Harmony Biosciences Holdings. Despite a period of executive and board refresh, Harmony’s share price has faced pressure, with a 90 day share price return of 25.79% decline and a 1 year total shareholder return of 10.43% decline. This suggests sentiment...